Merck & Co. Inc. has announced that the U.S. Centers for Disease Control and Prevention $(CDC)$ Advisory Committee on Immunization Practices (ACIP) has voted to recommend ENFLONSIA™ (clesrovimab-cfor) for preventing respiratory syncytial virus (RSV) lower respiratory tract disease in infants younger than 8 months who are born during or entering their first RSV season. The recommendation includes ENFLONSIA in the Vaccines for Children Program, ensuring broader access for infants. This follows the U.S. Food and Drug Administration's approval of ENFLONSIA based on clinical trials. Merck plans to start ordering in July 2025, with deliveries before the 2025-2026 RSV season. The ACIP's recommendation is provisional, pending final approval by the CDC Director or Health and Human Services Secretary.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.